Publication at First Faculty of Medicine |
2019
Abstract
In the KATHERINE trial, 1 486 patients with HER2- -positive breast cancer with residual invasive disease after pre-operative chemotherapy and trastuzumab, were randomly assigned to continue the adjuvant administration of trastuzumab, or they changed treatment for trastuzumab emtansine (T-DM1), monoclonal antibody trastuzumab covalently linked to the cytotoxic agent DM1 (emtansine). The risk of recurrence of breast cancer or death was lower in patients who received trastuzumab emtansine in comparison with patients that continued the treatment with trastuzumab by 50%, with an absolute difference of 11.3 % in the three-year invasive disease-free survival (IDFS).